Bench to Bedside - A Molecular Imaging Campaign
The Bench to Bedside Molecular Imaging Campaign
On June 4 at the SNM 2006 Annual Meeting in San Diego, SNM and the Education and Research Foundation for the SNM (ERF) announced the $5 million five-year Bench to Bedside fundraising initiative. The campaign was created after intensive dialogue with molecular and nuclear medicine imaging experts on the need to accelerate the translation of molecular imaging research into clinical practice for the benefit of patients worldwide.
Experts identified four primary areas for campaign investment:
- Supporting advocacy for molecular imaging
- Educating and promoting collaboration with referring physicians and patient groups
- Training and educating the current and future workforces on the applications of molecular imaging
- Supporting innovations in translational research
GE Healthcare, the Campaign's lead industry partner, helped jumpstart the initiative with an early pledge of $1,000,000. By November, Bristol-Myers Squibb, Siemens Medical Solutions USA, IBA Molecular, Philips and FlouroPharma joined the effort; followed in 2007 by MDS Nordion, Cardinal Health, Covidien (formerly Mallinckrodt, Inc), Mediso, and Molecular Insight Pharmaceuticals; and then by Bracco, Digirad, Hermes, Nuview, Medrad and Rotem in 2008. With the further support of Eckert & Ziegler and Bayer Schering Pharma AG in 2009, corporate investment in this initiative now stands at $4,721,000. That’s $221,000 over the goal!
Leading the Campaign drive for member support is the ERF, with a goal of raising $500,000—10% of the Campaign total—from individuals. SNM and ERF leaders initiated the member drive in June 2006. In 2007, the Pacific Southwest Chapter Technologist Section pledged $5,000 and agreed to match all its members’ gifts to ERF. By the end of January 2010, direct gifts and pledges have totaled more than $325,000.
We invite you to learn more about this important endeavor and invest in the future of your profession with a donation to the campaign.